Commercial Channels

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

Access Insights Conference delves into the latest obstacles, while mapping out potential solutions to address them.

A crash course on the bubble itself, including therapeutic areas most affected.

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

A panel dives into the current and future outlook of healthcare policies.

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.

The conference’s opening keynote sets the scene for 2025 and the years to come.

Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.

Results of the Phase III CENTERSTONE study demonstrated that when Xofluza is taken by an individual with influenza, it lowers the risk of others in the household contracting it.

It’s essential for commercial success, but presents its share of obstacles.

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization.

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence

Ashfield Event Experiences and WRG merge in an effort to better serve the healthcare industry.

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.

LillyDirect will facilitate access to medications by connecting patients with independent telehealth providers, bypassing the need to obtain a prescription from a physician and then going to a pharmacy to fill it.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Session discusses ways to integrate digital pharmacies and hubs.

Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.

Conference keynote offers an industry outlook, including new commercialization challenges.